Studies have shown that loss of heterozygosity (LOH) of TP53 and ESR is higher in ovarian serous cystadenocarcinoma (SCA) and more common in clear cell carcinoma (CCA) and serous tumor with low malignant potential (SLMP), which has been observed in primary ovarian tumors and metastases (65). The gene discussed is TP53; the disease is clear cell adenocarcinoma.